News

Office visits still common before colonoscopy


 

FROM JAMA

References

Nearly 30% of outpatient colonoscopies for colon cancer screening or polyp surveillance were preceded by a gastroenterology office visit, with that number reaching a staggering 50.5% in the South, according to an analysis of 842,849 middle-aged adults.

Patients with a higher Charlson Comorbidity Index (CCI) also were more likely to have an office visit. Still, 66.4% of patients with an office visit had a CCI of 0.

“Although the precolonoscopy office visits added a modest $36 per colonoscopy in this population, there are an estimated 7 million screening colonoscopies performed in the United States annually, so the cumulative costs are significant,” reported Dr. Kevin Riggs of Johns Hopkins University, Baltimore, and associates reported (JAMA. 2016 Feb 2. doi:10.1001/jama2015.15278).

The cost of precolonoscopy office visits has received little attention despite scrutiny of the high cost of colonoscopy in the United States and the availability of open-access colonoscopy since the 1990s, the authors noted.

The primary limitation of the study was the inability to determine the exact circumstances of the office visits. Patients with a diagnosis of colon cancer or inflammatory bowel disease in the prior 12 months were excluded from the analysis.

The study was funded by the National Institutes of Health and the National Cancer Institute. Dr. Riggs’ salary is supported by an NIH grant. Coauthor and colleague Dr. Craig Pollack reported stock ownership in the Advisory Board Company and that his salary is supported by a grant from the NCI.

pwendling@frontlinemedcom.com

Recommended Reading

Biomarker may ID high-risk colon cancers
MDedge Hematology and Oncology
Radiolabeled somatostatin analog has good showing in midgut neuroendocrine tumors
MDedge Hematology and Oncology
Everolimus is effective across diverse patients with GI neuroendocrine tumors
MDedge Hematology and Oncology
New neoadjuvant regimen for locally advanced rectal cancer is efficacious
MDedge Hematology and Oncology
Adjuvant oxaliplatin reduces colon cancer recurrence, deaths
MDedge Hematology and Oncology
High participation, steady sensitivity for CRC with annual FIT screening
MDedge Hematology and Oncology
Immune checkpoint inhibitors have antitumor activity in gastric, esophageal cancers
MDedge Hematology and Oncology
PD-1 blockade impresses in mismatch repair–deficient GI cancers
MDedge Hematology and Oncology
Survival of pancreatic cancer is better when adjuvant therapy is given in high-volume centers
MDedge Hematology and Oncology
RT for rectal cancer may reduce risk of some other cancers
MDedge Hematology and Oncology